Knowledge, attitude, and practice regarding pharmacovigilance among the general public in Western China: a cross-sectional study

References

• International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser. 1972;498:1–25.
   PubMedGoogle Scholar
• Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother.2013;4(Suppl 1):S73–S77.
   PubMedGoogle Scholar
• National Health and Family Planning Commission of the People’s Republic of China. Drug adverse reaction reporting and monitoring management measures (Ministry of Health of People’s Republic of China Order No.81); 2011 [cited 2011 Jul 1]. Available from: http://www.moh.gov.cn/mohzcfgs/pgz/201105/51770.shtml.
   Google Scholar
• National Medical Products Administration. The annual report on national adverse drug reaction monitoring in 2016 [cited 2019 Dec 19]. Available from: http://www.360doc.com/content/17/0508/00/1251068_652028391.shtml.
   Google Scholar
• National Medical Products Administration. The annual report on national adverse drug reaction monitoring in 2017 [cited 2019 Dec 19]. Available from: http://www.cdr-adr.org.cn/xwdt/201804/t20180418_20010.html.
   Google Scholar
• National Medical Products Administration. The annual report on national adverse drug reaction monitoring in 2018 [cited 2019 Dec 19]. Available from: http://med.china.com.cn/content/pid/148692/tid/3.
   Google Scholar
• Netherlands Pharmacovigilance centrelareb. Patient participation in pharmacovigilance [EB/OL].[2018-03-22]. Available from: https://www.lareb.nl/en.
   Google Scholar
• Fortnum H, Lee AJ, Rupnik B, on behalf of the Yellow Card Study Collaboration, et al. Yellow card study collaboration. Survey to assess public awareness of patient reporting of adverse drug reactions inGreat Britain.Clin Pharm Ther. 2012;37(2):161–165.
   Web of Science ®Google Scholar
• Government of Canada. Annual trends for the adverse reaction case reports of health products and medical device problem incidents to Health Canada (2008–2017) [EB/OL].(2018-10-31)[2019-05-27]. Available from: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/annual-trends-adverse-reaction-case-reports-health-products-medical-device-problem-incidents.html.
   Google Scholar
• Singh P, Agrawal M, Hishikar R, et al. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: analysis of spontaneous reports during 1 year. Indian J Pharmacol.2017;49(6):432–437.
   PubMed Web of Science ®Google Scholar
• Montastruc F, Bagheri H, Lacroix I, et al. Adverse drug reaction reports received through the Mobile App,VigiBIP®: comparison with classical methods of reporting. Drug Saf. 2018;41(5):511–514.
   PubMed Web of Science ®Google Scholar
• Ali S, Egunsola O, Al-Dossari D, et al. Adverse drug reaction reporting in a large tertiary hospital in Saudi Arabia: results of an incentive strategy. Ther Adv Drug Saf.2018;9(10):585–590.
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics of China. Ranking of provincial GDP per capita in 2018 [EB/OL].[2019-12]. Available from: http://www.stats.gov.cn/tjsj/ndsj/2019/indexch.htm2019.12.
   Google Scholar
• Xi’an Bureau of Statistics. The statistical bulletin of Xi'an 2019 national economic and social development [EB/OL].[2020-03-23]. Available from: http://www.xa.gov.cn/xw/gsgg/5e782b3a65cbd8132b680d8c.html.
   Google Scholar
• Xi’an Municipal People’s Government. National religion of Xi'an people's government [EB/OL].[2019-05-27]. Available from: http://www.xa.gov.cn/fqgg/cfgk/mczj/576529.html.
   Google Scholar
• Hariraj V, Aziz Z. Patient reporting of adverse drug reactions (ADRs): survey of public awareness and predictors of confidence to report. Ther Innov Regul Sci. 2018;52(6):757–763.
   PubMed Web of Science ®Google Scholar
• Mohammad A, Bheemavarapu H, Khan MU, et al. A cross-sectional survey to assess the knowledge, attitudes and common barriers to the reporting of adverse drug reactions by the general public in Malaysia. J Pharm Pract Res. 2018;48(4):348–355.
   Google Scholar
• Jha N, Rathore DS, Shankar PR, et al. Knowledge, attitude and practice regarding pharmacovigilance and consumer pharmacovigilance among consumers at Lalitpur District, Nepal. J Nepal Health Res Counc.2017;15(1):31–37.
   PubMedGoogle Scholar
• Staniszewska A, Dąbrowska-Bender M, Olejniczak D, et al. Patient knowledge on reporting adverse drug reactions in Poland. PPA. 2016;11:47–53.
   Web of Science ®Google Scholar
• Sales I, Aljadhey H, Albogami Y, et al. Public awareness and perception toward adverse drug reactions reporting in Riyadh, Saudi Arabia. Saudi Pharm J. 2017;25(6):868–872.
   PubMed Web of Science ®Google Scholar
• Pahuja R, Shrivastava B, Sharma PK, et al. Awareness on adverse drug reaction reporting system in India: a consumer survey. Am J Phytomed Clin Ther. 2014;2(12):1361–1369.
   Google Scholar
• Fortnum H, Lee AJ, Rupnik B, Yellow Card Study Collaboration, et al. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. J Clin Pharm Ther. 2012;37(2):161–165.
   PubMed Web of Science ®Google Scholar
• Li Z, An Y. The public awareness investigation of ADR among population in Shanghai. China Pharm. 2014;28(05):514–516.
   Google Scholar
• Lan CAI, Ya GAO, Jia-Wei LI, et al. Investigation and analysis on public cognition status for Adverse Drug Reaction in Guangdong Province. Chinese Pharm. 2015;26(21):2887–2889.
   Google Scholar
• Pan R. investigation and analysis on the awareness of adverse drug reactions in different populations. J Tradit Chinese Med Administration. 2015;23(24):14–16.
   Google Scholar
• Xu H, Wang Y, Liu N. A hospital-basedsurvey of healthcare professionals in the awareness of pharmacovigilance. Pharmacoepidemiol Drug Saf. 2009;18(7):624–630.
   PubMed Web of Science ®Google Scholar
• Jarernsiripornkul N, Patsuree A, Krska J. Public confidence in ADR identification and their views on ADR reporting: mixed methods study. Eur J Clin Pharmacol. 2017;73(2):223–231.
   PubMed Web of Science ®Google Scholar
• Elkalmi R, Hassali MA, Al-Lela OQ, et al. Adverse drug reactions reporting: knowledge and opinion of general public in Penang, Malaysia. J Pharm Bioallied Sci. 2013;5(3):224–228.
   PubMedGoogle Scholar
• McLernon DJ, Bond CM, Lee AJ, Yellow Card Study Collaboration, et al. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf. 2011;20(5):523–531.
   PubMed Web of Science ®Google Scholar
• Matos C, van Hunsel F, Joaquim J, et al. Are consumers ready to take part in the pharmacovigilance system?– a Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;71(7):883–890.
   PubMed Web of Science ®Google Scholar
• van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143–1150.
   PubMed Web of Science ®Google Scholar
• de LangenJ, van HunselF, PassierA, et al. Adverse *drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008;31(6):515–524.
   PubMed Web of Science ®Google Scholar